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Abstract: Previous research has shown beneficial effects of polyphenol-rich diets in ameliorating
cognitive decline in aging adults. Here, using a randomized, double blinded, placebo-controlled
chronic intervention, we investigated the effect of two proprietary blueberry formulations on cognitive
performance in older adults; a whole wild blueberry powder at 500 mg (WBP500) and 1000 mg
(WBP1000) and a purified extract at 100 mg (WBE111). One hundred and twenty-two older adults
(65–80 years) were randomly allocated to a 6-month, daily regimen of either placebo or one of the
three interventions. Participants were tested at baseline, 3, and 6 months on a battery of cognitive
tasks targeting episodic memory, working memory and executive function, alongside mood and
cardiovascular health parameters. Linear mixed model analysis found intervention to be a significant
predictor of delayed word recognition on the Reys Auditory Verbal Learning Task (RAVLT), with
simple contrast analysis revealing significantly better performance following WBE111 at 3 months.
Similarly, performance on the Corsi Block task was predicted by treatment, with simple contrast
analysis revealing a trend for better performance at 3 months following WBE111. Treatment also
significantly predicted systolic blood pressure (SBP) with simple contrast analysis revealing lower
SBP following intervention with WBE111 in comparison to placebo. These results indicate 3 months
intervention with WBE111 can facilitate better episodic memory performance in an elderly population
and reduce cardiovascular risk factors over 6 months.
Keywords: wild blueberry; flavonoid; anthocyanin; cognition; blood pressure; episodic memory;
older adults
1. Introduction
The number of people aged 60 years or older is expected to rise from 900 million to 2 billion
between 2015 and 2050, an increase from 12 to 22% of the global population [1]. From age 30 onwards,
it is well documented that individuals are subject to increasing cognitive decline which in turn can have
an impact on the general well-being, health, and financial status of the individual [2]. In particular,
domains of reasoning, problem solving skills, attention, processing speed, working memory, and
episodic memory become a significant societal problem as we age [3]. With levels of aging increasing
in the population, maintaining health and wellbeing in the elderly population by enhancing or slowing
decline in cognitive performance has become a major medical challenge.
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In the past few decades, the scientific community has started to study and understand the impact
of the Western diet on many non-communicable diseases and has demonstrated a clear beneficial
relationship between healthy nutrition and cognitive aging. For example, deleterious dietary habits
(overfeeding, high caloric/low dietary fiber diets or consumption of low antioxidant nutrients) and
sedentary lifestyle, or emotional stress, have been reported as key environmental factors for brain
disorders [4].
To date, a number of studies have observed protective associations between dietary polyphenols
and the prevention of age-related chronic diseases such as cardiovascular disease (CVD), diabetes,
cancers, osteoporosis and neurodegenerative diseases [4]. Blueberries are a particularly rich source of
polyphenolic compounds and contain a wide range of flavonoids (anthocyanins, catechins, quercetins,
proanthocyanidins) and phenolic acids (chlorogenic acids) [5,6]. Flavonoids, found in a variety of
fruits, vegetables, and beverages, are increasingly recognized as promising compounds mediating
a range of actions. Spencer [7] proposes that these involve the ability to protect vulnerable neurons,
enhance neuronal function, and stimulate regeneration via interaction with neuronal intracellular
signaling pathways involved in neuronal survival and differentiation, long-term potentiation (LTP),
and memory. Indeed, recent evidence suggests that the beneficial effects of flavonoids involve decreases
in oxidative/inflammatory stress signaling, increases in protective signaling, and neurohormetic effects
leading to the expression of genes that encode antioxidant enzymes, phase-2 enzymes, neurotrophic
factors, and cytoprotective proteins. Specific examples of such pathways include the sirtuin-FoxO
pathway, the NF-κB pathway, and the Nrf-2/ARE pathway. Together, these processes act to maintain
brain homeostasis and play important roles in neuronal stress adaptation. It can therefore be proposed
that polyphenols have the potential to prevent the progression of neurodegenerative pathologies.
Additionally, polyphenols have a well-documented role in vascularization, with recent evidence
demonstrating the effect of blueberry polyphenols on acute improvement of endothelium-dependent
flow mediated dilation which correlate with appearance of specific metabolites in plasma [8].
Together, these neurobiological and vascular changes result in both acute and chronic
improvements in memory and learning in both animals [7,9–11] and humans, with effects occurring
within 0–6 h as well as after repeated dosing [12–14]. In children, improvements have been observed
acutely following consumption of 200 g of blueberries in delayed recalled accuracy of the Rey’s
Auditory Verbal Learning Test (RAVLT) and in delayed word recognition of this same task following
consumption of 15 and 30 g of wild blueberry powder (WBP) respectively [15,16]. More recently,
Whyte et al. [17] manipulated cognitive demand in a modified attention network task finding that,
following acute intervention with 30 g WBP, children performed more effectively on the more
cognitively demanding trials of the task. This indicates that WBP intervention may be particularly
effective where cognitive demand or difficulty is comparatively high, and participants are not able
to perform the tasks at, or near, ceiling. In healthy older adults, 90-day supplementation with 24 g
of freeze-dried blueberry powder demonstrated significant improvement in repetition errors in the
California Verbal Learning Task (CVLT) and reduced switch cost on a task-switching test [18]. Linked
to the findings of Whyte et al. [17], Miller at al., noted that their significant findings were found on
the more challenging cognitive tasks in their battery. Similarly, in older adults with mild cognitive
impairment (MCI), participants showed better episodic memory performance on the CVLT and Verbal
Paired Associate Learning Test after 12-weeks consumption of 400–600 mL of wild blueberry juice [19].
In terms of neurological studies, 12-weeks supplementation with 30 mL daily blueberry concentrate
showed significant resting state increases in grey matter perfusion and increased activity in brain areas
significantly related to the cognitive tasks performed [20]. Additionally, Boespflug and colleagues [21]
found increased brain activation in the pre-central gyrus, middle frontal gyrus, and parietal lobe during
a working memory, n-back, task from 16 weeks blueberry supplementation, however no behavioral
benefits were found.
Together this previous evidence suggests that the exposure to flavonoids, and blueberry flavonoids
in particular, may be beneficial to episodic memory with some potential effects on other aspects of
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cognition, including executive function and working memory. However, more studies are needed
to help firmly establish an association between flavonoid dose, duration of exposure, and cognitive
performance [22]. Indeed, a recent systematic review concludes that the positive effects of food-based
anthocyanin consumption, the primary flavonoid component found in berries, on both acute and
long-term cognition appears promising [23]; and anthocyanins may be one of the components leading
to the efficacy of blueberries on cognition and vascularization. However, anthocyanins have low
bioavailability and, consequently, blueberry studies have typically had to utilize high doses that are
impractical for daily human consumption and reduce compliance in long term studies. Furthermore,
anthocyanins are relatively unstable in human body fluids at pH 7 and 37 ◦C, thus strategies to
improve anthocyanin bioavailability and influence their bioactivity are highly desirable. Naturex Inc,
has developed a formulation of wild blueberry extract and wild blueberry powder in combination with
thiol-components (L-cysteine and L-glutathione) that reduce anthocyanin degradation at physiological
conditions (patent number US7820207B2—Stabilized anthocyanin compositions).
The aim of this clinical study is to evaluate the safety and efficacy of daily wild blueberry extract
and blueberry powder stabilized with L-cysteine and L-glutathione on episodic and working memory,
executive function, mood and cardiovascular health over a 6-month period.
2. Materials and Methods
This study was reviewed and approved by the University of Reading Research Ethics Committee
and was given a favorable ethical opinion for conduct (Project identification code UREC 15/18).
All subjects gave their written informed consent for inclusion before they participated in the study.
The study was registered at clinicaltrials.gov NCT02446314.
2.1. Participants
Based upon a medium effect size (d = 0.640) observed in previous studies using grouped executive
function and episodic memory domains, we calculated that a sample size of 30 participants per
experimental group would provide a power of 0.96. One hundred and twenty-two independently
living healthy volunteers, 65–80 years old (mean = 70.8, SD = 3.88), of all ethnicity, with subjective
self-reported memory complaints were therefore included in the study.
Subjects were asked to maintain their normal eating habits and exercise habits to avoid any change
in body weight over the duration of the study. At the screening/familiarization visit participants
completed a number of questionnaires to check physical and mental health, and overall normal
cognitive functioning. The Mini-Mental State Examination (MMSE) was used to give a measure of
global cognitive function, the National Adult Reading Test (NART): to give a measure of premorbid
intellectual functioning, the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): to
give a measure of baseline cognitive function and Letter and category fluency: to measure aspects of
language and executive retrieval functions. Volunteers with an MMSE <24 were not included in the
study. Exclusion criteria included the use of complementary and alternative medicine (mostly food
supplements) for memory or cognitive performance within 1 month prior to study participation, history
of metabolic disorder, diabetes, substance abuse, diagnosis with psychiatric or neurological conditions,
use of medications that might affect the outcome measures (such as antidepressant and sleeping
medication), planned changes to current medication regime (treatment/dose), allergic reactions to
compounds similar to those in the investigational product, participation in other clinical trials within
the previous month or other cognitive trial within the previous 6 months, and drinking over 3 alcoholic
beverages per day or more than 12 alcohol units per day. Additionally, participants completed a 3-day
dietary record diary and YALE physical activity questionnaire in the seven days before the first and
last visit. Demographic details of the participants are shown in Table 1.
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Table 1. Demographic details of the participants.
Characteristic Mean SD Range
Age (at enrolment) 70.8 3.88 65–80
Males 47
Females 75
Weight (kg) 70.7 3.88 42.5–118.9
Height (m) 1.68 0.09 1.49–1.88
Average Daily Alcohol Units 1.3 1.51 0–10
MMSE 27.1 1.65 24–30
NART (Number of Errors) 9.3 6.49 0–38
CERAD (Learning) 20.9 3.14 10–29
CERAD (Delayed Recall) 5.6 2.22 0–10
CERAD (Word Recognition) 9.55 0.93 3–10
CERAD (Word Rejection) 9.75 0.71 6–10
Letter Fluency 16.8 5.09 6–30
Category Fluency 18.9 4.95 9–32
Frequency of Forgetting 1 5 0.76 2.8–6.9
Frequency of Forgetting 2 5.22 1.04 2.4–7
2.2. Treatments
The study used a randomized, double-blinded, placebo-controlled study to assess the safety
and efficacy of Wild Blueberry Powder and Wild Blueberry extract (ThinkBlue™, Naturex Inc,
South Hackensack, NJ, USA) in maintenance of episodic and working memory in older adults (Table 2).
Table 2. Nutritional composition of the three intervention products.
Group
Placebo Wild BlueberryPowder—500 mg
Wild Blueberry
Powder—1000 mg
Wild Blueberry
Extract 111 mg
Thinkblue™
Intervention
Wild Blueberry Powder (mg/dose) 0 450 900 0
Wild Blueberry Extract (mg/dose) 0 0 0 100
L-Cysteine (mg/dose) 0 45 90 10
L-Glutathione (mg/dose) 0 5 10 1
Artificially colored Maltodextrin (mg/dose) 1000 500 0 889
Nutritional
Analysis
Proteins (%) 1.0 8.4 15.8 10.5
Fat (%) 5.0 6.1 7.2 0.8
Fiber (%) 0.4 25.8 51.2 0.8
Sugars (%) 2.6 7.6 13.2 1.2
Vitamin C (ppm) 0.67 3.88 1.0 0
Total Anthocyanin (mg/dose) 0 1.35 2.7 7
Total Polyphenol (mg/dose) 0 35 70 50
The investigational products were encapsulated in transparent capsules and delivered in blister
packs of 16 capsules/week. The investigational products were manufactured by Naturex Inc and
the capsules and blisters by US Pharmalab Inc. The participants were instructed to take 2 capsules
daily and to return the left-over capsules by mail on a weekly basis to monitor compliance. The
placebo powder (consisting of maltodextrin and food grade artificial dye—blue and red lake) was color
matched to make these treatments indistinguishable, and to maintain blinding of both the investigator
and the study subject. Randomization of participants to treatment group was carried out using a
computerized random number generator (www.random.org) by Naturex Inc. Each subject entering
the study was assigned a participant’s number which corresponds to one of the four groups. The
relationship between the participant’s number and the treatment group was unknown to both the
investigators and the participants, i.e., the study was double-blinded. Unblinding only occurred
after the statistical analysis plan was signed and an analysis of the primary dependent variables
was completed.
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2.3. Cognitive Function
E-prime V2 (Psychology Software Tools, Inc., Sharpsburg, PA, USA) was used to display stimuli
and record participants responses. Audio stimuli were presented through noise cancelling enclosed
headphones. Blood pressure and pulse were measured using OMRON M6 BP machines (OMRON,
Hooffforp, Netherlands).
Both animal [9,11,24,25] and human [18,19,26–28] research has previously shown particular
benefits for both visuo-spatial and verbal episodic memory following flavonoid rich interventions
with older adults. Furthermore, in a review of acute flavonoid interventions, Bell [12] noted that one
would expect episodic memory benefits in older adults over and above other cognitive domains. The
primary outcome measures evaluated in the current study were therefore maintenance of episodic
memory assessed via three episodic memory tasks completed at week 0, 12 and 24. These tasks targeted
different visual and verbal components of episodic memory.
Firstly, the Rey’s Auditory Verbal Learning task (RAVLT) targeted verbal episodic memory and
examined performance in learning, memory recall, and recognition. The procedure followed that
previously described by Lezak [29], and as amended by Whyte, and Williams [17]. Measures of
immediate recall, total acquisition, amount learned, proactive and retroactive interference, delayed
recall, and word recognition were evaluated.
Secondly, visual episodic memory was assessed using an object recognition task. Here, 20 images
were presented each for 1000 ms with a 200 ms inter-stimulus interval. Approximately 25 min later,
these images were re-presented together with an additional 25 images (distractors). The subject was
asked to identify whether the image is the original or a new one. All images were drawn from the grey
scale version of the Snodgrass and Vanderwart picture set [30] and matched for familiarity, complexity,
and imagery.
Finally, we employed the Corsi Blocks task [31,32] as a measure of visual memory span [33] to
target short term spatial episodic memory. In this electronic version of the task, participants were
required to observe a sequence of blocks lighting up one at a time for a duration of 1000 ms. The
participant then repeats the sequence back in the same order by pressing the relevant blocks on the
screen. Sequence length was randomized and ranged from two to nine blocks. There were four
versions of each length giving a total of 32 sequences. Key outcome measures are the number of correct
sequences and the longest sequence remembered.
The secondary outcome measures evaluated working memory, selective attention and executive
function. Working memory was evaluated via completion of two different tasks, which consisted
of serial subtractions and Sternberg memory scanning. The serial subtractions tasks followed the
same procedure as described previously by Bell et al. [34]. Average response time and accuracy
were recorded.
The Sternberg memory scanning task [17,35] followed the same procedure as described previously
by Bell et al. [34]. Reaction time and accuracy were recorded for each trial. Additionally, the coefficient
of the line of best fit for reaction time versus memory set size was calculated to determine the scanning
rate of the participant, whilst mean reaction time was represented by the intercept.
Executive function, including selective attention, was measured using the Modified Attention
Network Task (MANT) and Stroop task. The MANT examines response interference, executive function
and attention. The task followed the same procedure as previously described by Whyte et al. [17],
with the exception that there were only two blocks each of which had a stimulus duration of 500 ms.
Additionally, no noise condition was included. Accuracy and response time were measured separately.
The Stroop task examines response interference, executive function and attention. The task
followed the procedure described previously by Bell et al. [34], with the exception that stimuli were
displayed with no time limit for responding. Accuracy and response time were measured separately.
The Positive and Negative Affect Schedule—NOW (PANAS-NOW), a reliable and valid self-report
measure [36,37], was used to determine positive and negative mood. Two scales, one for negative
affect and one for positive affect, were calculated.
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2.4. Markers of Cardiovascular Health
After the first half of the cognitive test battery, systolic and diastolic blood pressure, and heart
rate were measured three times in a row with a two-minute gap between each measurement. OMRON
M6 blood pressure machines (OMRON, Hooffforp, Netherlands) were used to take the measurements.
Subjects were in a seated position with their back against the chair. Mean scores were calculated for
each measure.
2.5. Food Diary
Participants completed two three-day food diaries with the initial diary completed between visits
1 and 2 and the second completed during the week before visit 6. Weighted food and drink was
recorded for two weekdays and one weekend day. These diaries were used to calculate habitual
fruit and vegetable, total flavonoid, and anthocyanin consumption at the beginning and end of the
study. Flavonoid content of food diary items was drawn from the USDA Database for the Flavonoid
Content of Selected Food [5]. Where food items were not represented in the USDA database, the Phenol
Explorer database was used [38] or a literature search was conducted for recent relevant flavonoid
content studies.
2.6. Procedure
The study comprised of six visits, including a screening/familiarization visit (week T-1), three
test visits (week 0, 12 and 24), and two control visits (week 6 and 18). Following the 1-week screening
period, subjects were randomized to consume either placebo, wild blueberry powder-500 mg, wild
blueberry power-1000 mg or wild blueberry extract-111 mg. All eligible participants consumed their
assigned capsules once daily orally with breakfast. On test days the capsules were consumed after the
cognitive battery had been completed.
During each test day, the participants attended the University of Reading labs at 0800 and first
consumed a standardized breakfast of two 40 g Pasquier Croissants, 25 g Philadephia Light cream
cheese and water ad libitum. Weight, height and wellbeing were then measured along with checks on
any changes to smoking, alcohol intake, medication, and any adverse effects of intervention. The tasks
used in this study have previously been shown to be sensitive to flavonoid interventions and are
suitable for use in this population. Participants performed the first five cognitive tasks; the Rey’s
Auditory Verbal Learning Task (RAVLT), Picture Recognition Task, Corsi Block Task, Stroop Task,
and Modified Attention Network Task (MANT). There was then a short break where blood pressure
and pulse were recorded three times in a row with a 2-min gap between each reading. The final
three cognitive tasks; the Serial 3 s, Serial 7 s, and Sternberg task were then performed, and then
finally the measure of mood, using the PANAS-NOW. In total the test session took no more than two
hours to complete. Multiple matched versions of the RAVLT and Corsi-Block task were constructed
and the order of presentation to participants was randomized across test sessions using a balanced
Latin square.
The control visits consisted of a check on wellbeing along with checks on any changes to smoking,
alcohol intake, medication, and any adverse effects of intervention. Following each test and control
visit, capsules for the following 6 weeks were administered.
2.7. Statistical Analysis
In order to account for familywise error, and according to a strict a-priori statistics plan, analysis
was limited to a restricted number of cognitive and cardiovascular outcomes (as detailed above
in task descriptions). All analysis was performed using SPSS v22 (IBM, Armonk, NY, USA) on a
per-protocol basis. Linear mixed modelling (LMM) was used to analyze cognitive and cardiovascular
data employing an unstructured matrix to model successive repeat measurements. Session, Dose, and
Session by Dose interaction were included as fixed factors in the model with baseline performance
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being included as a covariate. In the event of a significant interaction, data was split by time point
and two further one-way LMM analyses of Dose with baseline performance included as a covariate
were performed. Simple contrast analyses, with placebo as reference, were used to investigate any
significant main effects found in the above analyses. Outliers were removed based on comparison to
Standard Deviation (SD > 2SD) at each time point for each group. Given there were only two sets of
records, food diaries were analyzed employing an unstructured matrix to model successive repeat
measurements at time points one and six. Time point, Dose, and Time point by Dose interaction were
included as fixed factors.
3. Results
One hundred and twenty-two adults aged between 65 and 80 years were randomly allocated to
a 6-month, daily regimen of either placebo, 500 mg wild blueberry powder formulation (WBP500),
1000 mg wild blueberry powder formulation (WPB1000), or 111 mg wild blueberry extract formulation
(WBE111). One hundred and fifteen participants completed the full course, however, a further
three were subsequently excluded from the analysis, two were excluded due to beginning a course
of antidepressants during the study, and one for non-compliance in consumption of the capsules.
Participant numbers at each stage of the study are shown in Figure 1 below.
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Importantly there was also a significant intervention by session interaction (F(3,97) = 4.99, p = 0.003).
Data was therefore split by session and two one-way analyses were performed. For the Session
2 analysis, intervention significantly predicted performance (F(3,92) = 4.4, p = 0.006). As shown
in Figure 2, Post hoc simple contrast analysis, using placebo as the reference category, revealed a
significantly better performance following WBE111 intervention (mean = 0.926) in comparison to
Placebo (mean = 0.871) (p = 0.038). There were no significant effects at session 3.
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analyses were performed. For the Session 2 analysis, intervention significantly predicted performance
(F(3,101) = 4.05, p = 0.009). As can be seen in Figure 3, post hoc simple contrast analysis, using placebo
as the reference category, revealed a trend towards better performance following WBE111 intervention
(mean = 16.19) in comparison to Placebo ( ean = 15.14) (p = 0.069). There were no significant effects
found at session 3.
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There were no other treatment related significant effects or interactions for the Episodic
Memory analyses.
3.2. Markers of Cardiovascular Health
Systolic Blood Pressure (SBP)
The data from ten participants who were outliers was excluded from this analysis. There
was a significant effect whereby session predicted SBP (F(1,102) = 12.9, p = 0.001). Importantly,
intervention also significantly predicted SBP (F(1,102) = 2.88, p = 0.040). Post hoc simple contrast
analysis, using placebo as the reference category, revealed lower SBP following WBE111 intervention
(mean = 116 mmHg) in comparison to Placebo (mean = 122 mmHg) (p = 0.039). For WBE111, this
equates to a mean reduction of −3.08 mmHg between baseline and 3 months, and −6.99 mmHg
between baseline and 6 months, whereas for placebo there was an increase of 1.73 mmHg between
baseline and 3 months, and a decrease of only −3.19 between baseline and 6 months. As there was
no significant interaction, no further one-way analyses were performed. The mean scores for SBP by
group and time point are shown in Figure 4.
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In total, 283 dietary items classified as fruit or vegetables, and/or with flavonoid content, were
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Table 3. Mean daily Fruit and Vegetable (F and V), Total Flavonoid, and Anthocyanin (SD in parenthesis)
consumption by dose at visits 1 and 6 of study.
F and V (Portions) Flavonoid (mg) Anthocyanin (mg)
Visit 1 6 1 6 1 6
Placebo 4.22 (2.14) 4.23 (2.44) 802.40 (625.16) 762.63 (670.12) 27.14 (30.64) 29.33 (36.90)
WBE110 3.40 (1.75) 3.46 (1.86) 859.41 (512.89) 739.65 (564.32) 22.47 (35.12) 19.18 (21.33)
WBP500 3.47 (1.57) 3.60 (2.01) 756.65 (546.53) 755.03 (576.46) 33.59 (46.45) 33.92 (45.41)
WBP1000 4.19 (2.57) 3.98 (2.73) 789.47 (514.20) 753.97 (476.98) 28.96 (28.96) 22.80 (30.21)
4. Discussion
This is the first randomized double-blind, placebo-controlled study demonstrating an efficacy
of a proprietary formulation of blueberry containing as low as 50 mg of polyphenols, comprising
anthocyanins, flavanols, proanthocyanidins and chlorogenic acids (WBE111). Here we have shown
improved episodic memory performance in delayed word recognition and marginally significant
improved visuo-spatial Corsi Block performance at 3, but not 6, months following intervention
alongside a lowering of systolic blood pressure at both time points. No such effect was found for
the wild blueberry powders (WBP500 and WBP1000). Furthermore, no difference between groups
or between time points was found on any measure of fruit and veg, total flavonoid, or anthocyanin
consumption giving a clear indication that habitual diet was maintained over the six months of
the study.
It is of particular interest that the beneficial cognitive effects of our intervention were found
within the domain of episodic memory. This is in keeping with previous polyphenol-rich, chronic
blueberry interventions with older adults which have found positive memory related benefits on
the CVLT, a task similar to the AVLT used in the present study [18,19]. The fact this finding was
for word recognition is important as research from our lab has shown this task to be particularly
sensitive to flavonoid rich berry intervention in older adults [28] and children [15]. As was the case
with the current study, these effects were found in the absence of significant benefits in other memory
measures. It has been proposed that the cognitive benefits of flavonoid intervention are often found
when the task is cognitively challenging especially where stimuli are presented with some degree of
interference [17,18]. Word recognition requires that participants discern previously presented words
from an initial list whilst disregarding words from a second list and further novel interference words
all of which have been phonetically or semantically matched. Given the interference element of this
task, and taking previous findings into account, it can therefore be proposed that recognition memory
is particularly sensitive to flavonoid intervention. Though our visuo-spatial findings here did not
quite reach significance, beneficial effects of blueberry supplementation on visuo-spatial memory
in aging rats is well documented (for example [9,25]), and polyphenol-rich chronic interventions
with procyanidins have previously shown positive visuo-spatial benefits for older adults [26,27].
Importantly, the episodic verbal and visuo-spatial effects found in the current study were achieved
at a much lower blueberry anthocyanin dose (7 mg) than those used with older adults in previous
studies where typical doses were in the range of 269–621 mg daily [18–21]. This indicates that, due
to the stabilizing properties of the current formulation, it is possible to facilitate beneficial cognitive
effects with relatively low daily anthocyanin doses.
No positive effects were found for the executive function and working memory domains
considered in the current study. In a review of the polyphenol literature [13], Lamport and colleagues
note that, with the exception of isoflavones, positive effects of intervention are most often found within
the domain of declarative memory (though see [18,20]). Furthermore, in a review of the acute flavonoid
literature, Bell [12] found that, whilst executive function benefits might be found in young adults, this
was not the case for older adults who instead demonstrated most reliable improvements in episodic
memory. Given that it is well documented that episodic memory performance is known to decrease
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in older individuals; the findings in the current study indicate that this domain may be particularly
sensitive to polyphenol rich interventions within an older age group. This is consistent with previous
findings which have shown elevated or sustained levels of Brain Derived Neurotropic Factor (BDNF)
in ageing rats [9] and humans [28,39] following flavonoid-rich interventions. BDNF is known to be
involved in hippocampal function related to episodic memory and may enhance neuronal connections
or neuronal growth [12] leading to the improved memory performance demonstrated here.
The positive effects on cognition of lowering blood pressure in the elderly are well
documented [40] with recent reviews indicating that antihypertensive medication, particularly
Angiotensin II receptor blockers, benefit episodic memory in elderly individuals [41,42]. Though it
should be noted that our statistical plan was quite conservative in that it required the a-priori removal
of outliers to 2 SD from the mean, our findings are consistent with this previous research in that the
WBE111 both reduced systolic blood pressure and showed improved episodic memory at 3 months.
Additionally, previous research has shown that, following acute wild blueberry intervention, increases
in flavonoid metabolites coincide with increased flow-mediated dilation [8] and both acute [28] and
chronic [20] blueberry interventions have shown increased resting state perfusion in younger and
older adults respectively. Interestingly, again following chronic wild blueberry interventions, increased
BOLD activation can be found in task related brain areas for both executive function Stroop [20] and
working memory N-Back [21] tasks. Though, as yet, no wild blueberry study has considered brain
activation in relation to episodic memory, our findings relating to improved vascular function indicate
that one possible mechanism by which the WBE111 intervention is having an effect is via increased
perfusion in task relevant areas such as the hippocampus.
As noted above, there was lack of any significant WBP-related cognitive or cardiovascular effects.
One possible explanation for this finding may be the different flavonoid and polyphenol content of
each treatment. Though the WBP1000 treatment contained a higher total polyphenol content (70 mg) in
comparison to WBE (50 mg), the total WBP anthocyanin content (2.7 mg) was lower than WBE (7 mg).
The WBP500 treatment was lower than WBE111 in both total polyphenol (35 mg) and anthocyanin
(1.35 mg) content. Given the growing body of research relating flavonoid interventions to improved
cognition [12–14] it is probable that anthocyanins may be a critical component in the positive effects
found here. The lack of positive effects found for WBP500 and WBP1000 may therefore be due to the
lower anthocyanin dose in these treatments not being sufficient to produce a beneficial effect. Further
research considering doses equivalent or higher to the WBE111 treatment is therefore recommended.
Alternatively, the microstructure of the extract in comparison to the powders should also be considered.
The extract is devoid of fibers and water soluble while the full spectrum powders are very rich in
insoluble fibers to which the polyphenols are bound. It is therefore possible to hypothesize that the
polyphenols in the powders were not as bioaccessible as in the extract, and therefore less efficacious.
It should be noted that Miller et al. (2017) found improved cognitive function following a full spectrum
intervention with older adults, albeit at a much higher dose than those used here. It is therefore
recommended that future research considers the effect of composition and dose of treatments to
ascertain whether cognitive improvements can be achieved at lower anthocyanin doses in relation to
level of fiber content.
The lack of a significant difference between the treatments at 6 months was unexpected. It is
possible that the 6-month findings may indicate an element of practice effect whereby participants
improved their strategy on performing these memory tasks thus reducing task sensitivity to
intervention. Indeed, regardless of treatment, significant main effects of session were seen for both
Corsi and Word Recognition indicating a general improvement in performance of these tasks across
time. It should be noted that previous blueberry intervention fMRI research has found increased
brain activation during cognitive tasks which was not mirrored in improved task performance again
indicating a lack of task sensitivity to intervention [20,21]. It could therefore be argued, the fact that
reduced systolic blood pressure was maintained for the WBE111 treatment in comparison to all other
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treatments at 6 months whilst the cognitive benefit was no longer evident is consistent with this task
sensitivity hypothesis.
Furthermore, the lack of significant findings at 6 months may be due to possible degradation
of the active constituents in the capsules, or increased tolerance to the WBE, leading to a decrease
in efficacy nearing the end of the study. This in turn may have reduced any differences between the
interventions at this second time point. Analysis of the capsule contents were not measured during
the current study, nor were any physical measures of flavonoid metabolism taken, precluding any
definitive conclusions regarding these potential confounds. However, research should consider these
as additional measurements across the duration of future studies.
Finally, there was a lack of mood effects found at any time point during the study. The mood
measurements were taken at the end of a 1.5 h task session. Participants by this point were mentally
fatigued and also could conceivably have been affected by their perception of how they had performed
on the demanding task battery. This may in turn have confounded any positive or negative mood
effects related to the interventions. To control for this, future research should consider measuring
mood both before and after the task battery allowing for comparisons to be drawn on mood change
between and during test sessions.
5. Conclusions
The results indicate that 3 months intervention with WBE111 can facilitate better episodic memory
performance and improve cardiovascular function over 6 months. The doses used in this study were
comparatively small compared to previous research and it is therefore interesting to see an effect even
at such low dose. Effects were not found, however, for the working memory, executive function, and
mood tests, and further research investigating the efficacy of interventions on these domains with
higher daily doses is currently in train.
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